Oncocross
Oncocross is a South Korea-based, KOSDAQ-listed AI precision medicine company using multi-omics analytics platforms — RAPTOR AI and ONCOfind AI — to enable pharmaceutical and research partners in drug discovery, indication expansion, biomarker development, and early cancer detection.
- Company typePublic
- Founded2015
- HeadquartersMunjeongildong, South Korea
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Oncocross does
Oncocross Co., Ltd. is a South Korea-based, KOSDAQ-listed (ticker 449740, listed December 2024) AI-driven precision medicine company operating across drug discovery, diagnostics, and data assetization. The company was founded in June 2015 and built around a multi-omics AI platform that integrates transcriptomics, proteomics, metabolomics, and spatial proteomics data to support pharmaceutical and medical research partners. Its product portfolio consists of four interrelated layers: Neo Omics, an LC/MS-based multi-omics analysis service with end-to-end automation; the Digital Bio-Bank (DBB), a data assetization platform linking clinical (RWD), omics, and pathology data across 10,000+ clinical/genomic records and 2,700+ biospecimens; ONCOfind AI, a blood-based liquid-biopsy platform for cancer-of-unknown-primary prediction, early cancer detection, and post-treatment monitoring; and RAPTOR AI v2.0, the next-generation indication-discovery and mechanism-interpretation engine that also supports new modalities such as ADCs, bispecific antibodies, and targeted protein degraders. The company also operates an internal drug pipeline (OC212e for anti-cancer, OC901 for neurodegenerative disorders) and partnered/optioned assets (OC514 licensed to Korea Pharma for sarcopenia after completing Phase I; DW1023 jointly developed with Daewoong Pharmaceutical).
Oncocross firmographics
Firmographics- Name
- Oncocross
- Legal name
- ONCOCROSS CO., LTD.
- Website
- https://oncocross.com
- Company type
- Public
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Oncocross is a South Korea-based, KOSDAQ-listed AI precision medicine company using multi-omics analytics platforms — RAPTOR AI and ONCOfind AI — to enable pharmaceutical and research partners in drug discovery, indication expansion, biomarker development, and early cancer detection.
- Ownership category
- akta.pro rank
Oncocross industry classification
Industry- Product category
- AI-Driven Drug Discovery & Precision Medicine
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Analytical Laboratory Instrument Manufacturing (334516)
- SIC
- Services-Commercial Physical & Biological Research (8731), Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industries
- Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics) (HLAAANAF), AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)
Keywords
Where Oncocross is headquartered
LocationHeadquarters
- HQ city
- Munjeongildong
- HQ country
- South Korea
- HQ region
- Asia
Offices2 records
Markets served
Oncocross business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales
Revenue model
- Project-based Services (Neo Omics): Multi-omics analysis services for cell, tissue, and liquid specimens provided on a project basis. Starting point for service revenue.
- Joint Research & Development: Collaborative drug discovery partnerships with pharmaceutical companies for indication expansion, target discovery, and biomarker development. Revenue from research collaboration fees and potential milestone payments.
- Licensing & Technology Transfer: License-out of proprietary drug candidates (e.g., OC514 to Korea Pharma) and technology transfer agreements.
- Data Services & Analytics: DBB-based data analytics, biomarker discovery, and precision medicine data services leveraging integrated clinical and multi-omics datasets.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Professional services/ project-based | Project-based | Custom project-based pricing |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels4 records
Oncocross product offering
Product offeringCore offering
Oncocross develops and operates AI-driven precision medicine platforms that combine multi-omics data (transcriptomics, proteomics, metabolomics, spatial proteomics) with proprietary AI models to support pharmaceutical drug discovery, cancer diagnostics, and data assetization. Its commercial offerings include the RAPTOR AI® and ONCOfind AI® platforms, a fee-for-service multi-omics laboratory business (Neo Omics), and a Digital Bio-Bank (DBB) data assetization platform, sold through direct enterprise engagement with pharmaceutical companies and research institutions.
Product overview
Oncocross operates as a platform-based AI-driven precision medicine company with four integrated core products: Neo Omics (LC/MS-based multi-omics analysis service), DBB (Digital Bio-Banking for clinical-omics-pathology data assetization), ONCOfind AI® (multi-omics-based early cancer detection, primary site prediction, and post-treatment monitoring), and RAPTOR AI® VERSION 2.0 (AI platform for indication discovery, mechanism interpretation, and new modality development). The company also develops proprietary drug pipelines (OC212e — anti-cancer, OC901 — neurodegenerative disorders, OC514 — sarcopenia completed Phase I) and partnered pipelines (DW1023 with Daewoong). The portfolio spans from multi-omics data generation through data assetization to AI-powered diagnostics and drug discovery.
Differentiator
Problem solved
Functional benefit
Brands
- OncoMaster: Clinical and genomic data platform acquired and integrated by Oncocross, serving as the foundation for Digital Bio-Bank (DBB) and precision medicine data business.
Products and services
- RAPTOR AI® Version 2.0 Next-generation AI platform that supports candidate indication discovery, mechanism-of-action interpretation, and new modality development (ADCs, bispecific antibodies, TPD) based on Asian multi-omics data and automated experimental infrastructure. Sold to pharmaceutical and biotech partners for drug discovery R&D.
- ONCOfind AI® AI-powered multi-omics analytics platform integrating blood-based genomic, transcriptomic, proteomic, and metabolomic data for cancer primary site prediction, early cancer detection, and post-treatment monitoring. Targets diagnostic and clinical applications.
- Neo Omics
Quantifiable outcome
- 150+ scientific publications in peer-reviewed journals demonstrating platform capabilities
- +2 more outcomes
Companies that use Oncocross
Customer profileNamed customers8 records
Segments3 records
Ideal customer profiles3 records
Oncocross technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature4 records
Oncocross partnerships and signals
Strategic signalPartnerships
48 partnerships are on record, tiered core and minor.
- OncoMastercoreAbsorption merger decision (April 2026) with merger ratio of 1:5.2100960. OncoMaster's clinical and genomic data assets integrated with Oncocross's AI platform.
- Human & BiocoreVascular tissue-based AI biomarker joint research.
- Omics AIcoreStrategic investment of KRW 2 billion in Omics AI, combining the investment with OmicsAI's automation system to promote popularization of high-cost protein analysis services through automation.
- Chung-Ang University HospitalcoreJoint business agreement on AI-based digital biobanking.
- UNISTcoreJoint research team identified new metabolomic biomarkers for precision liver cancer diagnosis.
- Chonnam National University Hwasun HospitalcoreAI-driven future medicine research collaboration.
- Chonnam National University Hwasun HospitalcoreAI future medicine research collaboration.
- AptiscoreNational project on AI-based next-generation ADC therapeutics development.
- Université Laval / ARSACS FoundationcoreRare disease drug development collaboration with Canadian university and foundation.
- Université Laval / ARSACS FoundationcoreRare disease drug development project with Canadian university.
- Variational AI Inc.coreAI-based joint drug development research collaboration with Canadian AI company Variational AI.
- Variational AI Inc.coreAI-based joint drug development research collaboration.
- Seoul National University HospitalcoreNext-generation AI drug development research collaboration with Seoul National University Hospital.
- Variational AI Inc.coreDrug development collaboration with Canadian AI company.
- Variational AI Inc.coreAI-based joint drug development collaboration.
- Variational AI Inc.corePartnership for AI-powered drug discovery development.
- Seoul National University HospitalcoreJoint AI drug development research collaboration.
- Variational AI Inc.coreAI drug development research collaboration with Canadian company.
- Variational AI Inc.coreResearch collaboration with Canadian AI company for drug development.
- Seoul National University HospitalcoreJoint research for next-generation AI drug development.
- Korea University Medical Center / KCMC HoldingscoreK-Bio technology commercialization model with 148 licensing agreements and $55.3M contract value; M&A outcome including oncoMASTER merger into Oncocross.
- Kine SciencecoreDrug evaluation service on peptide asset.
- JW PharmaceuticalcoreDrug evaluation service for indication expansion of 3 drugs under development.
- BoryungcoreIndication expansion collaboration for KANARB (hypertension treatment) using AI-driven drug repurposing.
- AlphaMol SciencecoreLiver disease treatment drug joint research and development collaboration with Swiss biotech AlphaMol.
- Gachon University Gil Medical CentercoreMOU for collaborative research and medical AI development.
- Cyclica Inc.corePartnership for therapeutic development in oncology and myelofibrosis treatment using Cyclica's AI-powered drug discovery platform combined with Oncocross's multi-omics capabilities.
- Donghwa PharmaceuticalcoreAnti-cancer drug research collaboration using Oncocross's AI platform.
- 4P Pharma (Institut Pasteur de Lille)coreRare disease drug research collaboration with French biotech 4P Pharma.
- Korea University Anam HospitalcoreAI-based clinical research collaboration.
- Austria Wirtschaftsservice (AWS)minorSelected for GO AUSTRIA program organized by Austrian government (2021).
- CytogencoreResearch collaboration agreement.
- 365mccoreAI-powered obesity treatment drug development using inhalation fat research.
- UC Berkeley SkyDeckminorSelected for SkyDeck accelerator program at UC Berkeley (2021).
- Daewoong PharmaceuticalcoreStrategic investment and joint research collaboration for drug indication expansion. Daewoong invested in Oncocross while collaborating on AI-driven drug development.
- Samsung Medical CentercoreResearch collaboration agreement for AI drug discovery.
- Columbia University Medical CentercoreResearch collaboration with prestigious US academic medical center.
- HLBcoreAnti-cancer drug development MOU.
- CHA Bundang Medical CentercoreMOU for collaborative research.
- Choong Nam UniversitycoreAI drug discovery research collaboration MOU.
- Cyclica Inc.coreJoint research collaboration agreement.
- HLR Life SciencescoreAnti-cancer drug development MOU.
- Bundang CHA HospitalcoreMedical AI research collaboration.
- ST PharmcoreCOVID-19 & Dengue Fever research collaboration.
- Cancer Research UKcoreMaterial Transfer Agreement (MTA) for cancer research.
- Seoul National UniversitycoreMOU on PharmDB-K research collaboration.
- MD Anderson Cancer CentercoreClinical Development Agreement (CDA) on sarcopenia treatment.
- Korea Research Institute of Chemical TechnologycoreMOU for collaborative research.
Scale indicators8 records
Recent moves8 records
Expansion highlights6 records
Oncocross competitors and assessment
Company assessmentDirect peers
- Recursion Pharmaceuticals: AI-driven drug discovery platform combining multi-omics data with automated wet-lab experimentation to develop small-molecule therapeutics - directly overlapping Oncocross's RAPTOR AI drug discovery model and target/biomarker discovery use cases.
- Insitro: Machine learning platform that integrates multi-omics data, phenotypic screening, and disease modeling for drug discovery - directly comparable to Oncocross's RAPTOR AI approach of combining multi-omics and AI for indication discovery.
- Exscientia: AI-driven precision medicine company using patient-derived multi-omics data for drug discovery and indication expansion - directly aligned with Oncocross's indication discovery and partnered pharma collaboration model.
- Standigm: Korean AI drug discovery company applying machine learning to identify novel therapeutic targets and drug candidates - direct domestic peer with same Korean pharma customer base and overlapping indication-expansion capabilities.
- Cyclica: AI-augmented drug discovery platform with multi-omics integration for polypharmacology and target discovery - directly comparable to Oncocross's RAPTOR AI, and notably already a strategic partner (2022 joint research agreement).
- Benevolent AI: AI platform combining biomedical knowledge graphs with multi-omics data for target identification and drug discovery - similar AI-for-pharma model with comparable partnership-driven revenue structure.
- Deargen: Korean AI-driven drug discovery company focused on novel target identification using deep learning over multi-omics data - direct domestic peer competing for same Korean pharma partnerships and pipeline assets.
- Guardant Health: Liquid biopsy and multi-omics-based cancer diagnostics company with blood-based early detection and monitoring capabilities - directly comparable to Oncocross's ONCOfind AI diagnostic platform for cancer detection and treatment monitoring.
Broad incumbents
- Schrödinger: Physics-based computational platform for molecular simulation and drug discovery with broader materials science footprint - competes in same AI drug discovery category as Oncocross but operates as established software-plus-collaborations incumbent.
- BGI Genomics: Asia-headquartered genomics and multi-omics services provider with large-scale sequencing, proteomics, and bioinformatics - comparable as broader incumbent in multi-omics data generation and Asian precision medicine data assets.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Oncocross social profiles
Digital presenceOncocross financial estimates
Financial estimateRevenue estimate
Valuation estimate
Oncocross leadership team
Management profileNumber of profiles
Profiles7 records
Oncocross subsidiaries and ownership
Company hierarchySubsidiaries3 records
Oncocross funding detail
Funding detailFunding overview
Funding rounds7 records
Investors21 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Oncocross M&A and investment
M&A and investmentM&A
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Oncocross
What does Oncocross do?
Oncocross develops and operates AI-driven precision medicine platforms that combine multi-omics data (transcriptomics, proteomics, metabolomics, spatial proteomics) with proprietary AI models to support pharmaceutical drug discovery, cancer diagnostics, and data assetization. Its commercial offerings include the RAPTOR AI® and ONCOfind AI® platforms, a fee-for-service multi-omics laboratory business (Neo Omics), and a Digital Bio-Bank (DBB) data assetization platform, sold through direct enterprise engagement with pharmaceutical companies and research institutions.
Is Oncocross a public or private company?
Oncocross is a public company. It is classified as public and is currently operating.
When was Oncocross founded?
Oncocross was founded in 2015. It employs 11 to 50 people.
Where is Oncocross based?
Oncocross is headquartered in Munjeongildong, South Korea, in the Asia region.
How does Oncocross make money?
Four revenue lines are on record. Project-based Services (Neo Omics) is the primary driver. The others are joint Research & Development, licensing & Technology Transfer and data Services & Analytics.
Who are Oncocross's main competitors?
Direct peers on record are Recursion Pharmaceuticals, Insitro, Exscientia, Standigm, Cyclica, Benevolent AI, Deargen and Guardant Health. Broad incumbents are Schrödinger and BGI Genomics.
Does Oncocross have an API?
No public API is recorded for Oncocross.
What industry is Oncocross in?
Oncocross's product category is AI-Driven Drug Discovery & Precision Medicine. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAANAF, Multi-Omics Precision Medicine Platforms (genomics/proteomics/metabolomics). Its NAICS code is 541714 and its SIC code is 8731.